Literature DB >> 11384099

Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.

A Scorilas1, A Karameris, N Arnogiannaki, A Ardavanis, P Bassilopoulos, T Trangas, M Talieri.   

Abstract

Matrix metalloprotease-9 (MMP-9; 92 kDa type IV collaganase, gelatinase B) is regarded as, important for degradation of the basement membrane and extracellular matrix during cancer invasion and other tissue-remodelling events. In this study we evaluate the prognostic value of MMP-9, by immunoperoxidase staining in a series of 210 breast cancer tissues. The results were quantitated using the HSCORE system, which consider both staining intensity and the percentage of cells stained at given intensities. MMP-9 status was compared with the concentration of cytosolic Cathepsin-D and with other established prognostic factors, in terms of disease free survival and overall survival. The median follow-up period was 62 months. MMP-9 staining was observed primarily in cancer cells, and to a lesser degree in surrounding stromal cells. MMP-9 expression was not detected in normal breast tissue. Levels of MMP-9 expression below the cut-off point were more frequently observed in larger (P = 0.014), invasive ductal histologic (P = 0.037), progesterone receptor (PR)-negative and PR-strong positive tumours (P< 0.001), as well as samples belonging to patients with stage III-IV disease (P = 0.009) and age 45-55 years (P = 0.011). In univariate analysis, node-negative breast cancer patients with tumors positive for MMP-9 had a considerable reduction in risk for relapse (RR = 0.45;P = 0.039) or death (RR = 0.32;P = 0.009). Multivariate analysis indicated that MMP-9 status was an independent favourable predictor of OS (RR = 0.47;P = 0.034) in node-negative but not in node-positive patients. Our results suggest that MMP-9 may be an independent favourable prognostic factor in node-negative breast cancer patients. The overexpression of MMP-9 in breast cancer may be also used as a marker to subdivide node negative breast cancer patients in order to determine the optimal treatment modality. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384099      PMCID: PMC2363667          DOI: 10.1054/bjoc.2001.1810

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  49 in total

1.  Laminin receptors, collagenase IV and prognosis in node-negative breast cancers.

Authors:  M G Daidone; R Silvestrini; A D'Errico; G Di Fronzo; E Benini; A M Mancini; S Garbisa; L A Liotta; W F Grigioni
Journal:  Int J Cancer       Date:  1991-06-19       Impact factor: 7.396

2.  Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.

Authors:  J L Jones; P Glynn; R A Walker
Journal:  J Pathol       Date:  1999-10       Impact factor: 7.996

3.  Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis.

Authors:  A Scorilas; J Yotis; C Pateras; T Trangas; M Talieri
Journal:  Clin Cancer Res       Date:  1999-04       Impact factor: 12.531

4.  Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9.

Authors:  E Mira; S Mañes; R A Lacalle; G Márquez; C Martínez-A
Journal:  Endocrinology       Date:  1999-04       Impact factor: 4.736

Review 5.  Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications.

Authors:  S Zucker; M Hymowitz; C Conner; H M Zarrabi; A N Hurewitz; L Matrisian; D Boyd; G Nicolson; S Montana
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

6.  MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate.

Authors:  R Hanemaaijer; C F Sier; H Visser; L Scholte; N van Lent; K Toet; K Hoekman; J H Verheijen
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

7.  Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer.

Authors:  S M Thorpe; I J Christensen; B B Rasmussen; C Rose
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 8.  Type IV collagenases in invasive tumors.

Authors:  K Tryggvason; M Höyhtyä; C Pyke
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence.

Authors:  D W Visscher; M Höyhtyä; S K Ottosen; C M Liang; F H Sarkar; J D Crissman; R Fridman
Journal:  Int J Cancer       Date:  1994-11-01       Impact factor: 7.396

10.  Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.

Authors:  A Scorilas; J Yotis; D Gouriotis; A Keramopoulos; K Ampela; T Trangas; M Talieri
Journal:  Anticancer Res       Date:  1993 Sep-Oct       Impact factor: 2.480

View more
  61 in total

1.  Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Authors:  Dan Guo; Jiayi Huang; Jianping Gong
Journal:  Mol Cell Biochem       Date:  2011-12-14       Impact factor: 3.396

2.  Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables.

Authors:  J Decock; W Hendrickx; H Wildiers; M R Christiaens; P Neven; M Drijkoningen; R Paridaens
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Hispolon inhibits TPA-induced invasion by reducing MMP-9 expression through the NF-κB signaling pathway in MDA-MB-231 human breast cancer cells.

Authors:  Yi-Sheng Sun; Zhao Zhao; Han-Ping Zhu
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

4.  Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth.

Authors:  Annette Lebeau; Claudia Müller-Aufdemkamp; Clarissa Allmacher; Ulrich Sauer; Andreas Nerlich; Ralf Lichtinghagen; Udo Löhrs
Journal:  J Mol Histol       Date:  2004-06       Impact factor: 2.611

5.  Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C.

Authors:  Tobias N Dechow; Laura Pedranzini; Andrea Leitch; Kenneth Leslie; William L Gerald; Irina Linkov; Jacqueline F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.

Authors:  Michelle D Martin; Kathy J Carter; Sharon R Jean-Philippe; Mayland Chang; Shahriar Mobashery; Sophie Thiolloy; Conor C Lynch; Lynn M Matrisian; Barbara Fingleton
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Hee Jung Kim; Chan-il Park; Byeong Woo Park; Hy-de Lee; Woo Hee Jung
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

8.  Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

Authors:  María M Caffarel; Clara Andradas; Emilia Mira; Eduardo Pérez-Gómez; Camilla Cerutti; Gema Moreno-Bueno; Juana M Flores; Isabel García-Real; José Palacios; Santos Mañes; Manuel Guzmán; Cristina Sánchez
Journal:  Mol Cancer       Date:  2010-07-22       Impact factor: 27.401

9.  Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9.

Authors:  Dengfeng Cao; Kornelia Polyak; Marc K Halushka; Hind Nassar; Nina Kouprina; Christine Iacobuzio-Donahue; Xinyan Wu; Saraswati Sukumar; Jessica Hicks; Angelo De Marzo; Pedram Argani
Journal:  Breast Cancer Res       Date:  2008-10-27       Impact factor: 6.466

10.  Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness.

Authors:  E Blot; W Chen; M Vasse; J Paysant; C Denoyelle; J-Y Pillé; L Vincent; J-P Vannier; J Soria; C Soria
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.